Olav Aga Kildal on Muck Rack

Olav Aga Kildal

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Olav Aga

Contact Olav Aga, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Tyrosine kinase inhibitors in Kosaki/Penttinen syndromes: new reports, follow-up of treated individuals and literature review

|
By Celine Jost, Alessandro Mussa, Jean-Emmanuel Kurtz, Ann Nordgren, Silvia Kalantari, Diana Carli, Andrea Gazzin, Claudio Isella, Enzo Medico, Thirona Naicker, Antoinette V. Chateau, Jean-Baptiste Demoulin, Nikolas Herold, Tara L. Wenger, Helena Iznardo, Eulalia Baselga, Jose Mascaro, Cecilie Bredrup, Titas Gladkauskas, Cecilie F. Rustad, Dinel Pond, Élise Schaefer, Maxime Luu, Marc Bardou, Laurence Faivre, Ashmika Gokhul, Anna Cassisa, Daniela Cantarella, Yordi-Michaël Bouhatous, Liubinka Mirakovska, Agnès Maurer, Théo Gaumet, Olav Aga Kildal, Ingrid Voktor Svinvik
| Nature Verified
Abstract Heterozygous activating variants in platelet-derived growth factor receptor beta (PDGFRβ) are associated with ultra-rare and clinically heterogeneous conditions, including KOGS (Kosaki Overgrowth Syndrome), PS (Penttinen Syndrome) and related conditons. Tyrosine kinase inhibitors (TKIs), which are widely used in hematological and oncological diseases, are now being explored as potential treatments for these conditions.
Open in Who Shared Issue with article?
See all 1 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified